October 10, 2015 News by Patricia Silva, PhD EXCLUSIVE: Genentech/Roche Interview with MS News Today on Promising MS Therapy Ocrelizumab #ECTRIMS 2015 Dr. Peter Chin, a renowned neurologist and Principal Medical Director of Global Neuroscience Development at Genentech, a leading biotechnology company and member of the Roche Group, participated in an exclusive interview with Multiple Sclerosis News Today correspondent Dr. Ana de Barros on the companyās promising multiple sclerosis (MS) therapy…
October 10, 2015 News by BioNews Staff Mike Nace, Editor-in-Chief of Multiple Sclerosis News Today, Reviews Day 2-3 at #ECTRIMS2015 https://multiplesclerosisnewstoday.com/wp-content/uploads/2015/10/ECTRIMS-Podcast-2-091015-8.32-pm.mp3 Read theĀ articles mentioned in theĀ podcast: #ECTRIMS2015 ā Another Attendee Record #ECTRIMS2015 ā āVitamin D plays important role in MS inflammation.ā ā Jorge Correale #ECTRIMS2015 ā āWhen you stop smoking you can decrease the risk of disease progression.ā ā Jorge Correale Discovering a New World in…
October 9, 2015 News by Patricia Silva, PhD Genzyme Provides Update on Lemtrada for Patients with Relapsing-Remitting Multiple Sclerosis, ECTRIMS 2015 Genzyme, aĀ SanofiĀ company, recently announced novel positive 5-year experimental dataĀ from the extension study of LemtradaĀ®Ā (alemtuzumab) in individuals with relapsing-remitting multiple sclerosis (RRMS). The findings were presented today, October 9, at the 31stĀ Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain. LemtradaĀ®Ā (alemtuzumab), developedĀ by Genzyme, is…
October 9, 2015 News by Margarida Azevedo, MSc Promising Data on ZINBRYTA (Daclizumab High-Yield Process) Compared to Interferon Beta-1a in RRMS, ECTRIMS 2015 Lead scientists representing Biogen and AbbVie presented new data on clinical results from the Phase 3 study DECIDE on the compound ZINBRYTA TM at the 31st Congress of the European Committee for Treatment and Research in MS (ECTRIMS) in Barcelona, Spain. The full results of the 2 to 3-year long…
October 9, 2015 News by Patricia Silva, PhD Biometrica MS Launched at ECTRIMS 2015 to Support Routine Multiple Sclerosis Care Biometrica MS, a technology that provides an easy to use service for neurologists to quantify lesion load as well as brain volume measures in clinical practice, is a web-based image analysis tool that was recently launched at the 31st Congress of the European Committee for Treatment and Research in Multiple…
October 9, 2015 News by Malika Ammam, PhD Gilenya’s Clinical Trial Results Presented at ECTRIMS Reinforce Long-Term Efficacy Profile in RMS Patients On October 8, 2015, data on two Phase III clinical trials called FREEDOMS and FREEDOMS II on Gilenya (fingolimod), a drug developed byĀ Novartis, were presented at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), currently being held in Barcelona, Spain (October 7-10).
October 9, 2015 News by Patricia Silva, PhD EXCLUSIVE: Top MS Researcher Gives Interview With MS News Today After Presenting New Data on Biogen’s TECFIDERA at #ECTRIMS2015 A top MS researcher for Biogen Idec answered questions in an exclusive interview with Multiple Sclerosis News Today correspondent Dr. Ana de Barros at a Satellite Symposia entitled āMS developments: transitioning evidence into clinical practiceā presentedĀ by the companyĀ this morning at the 31st Congress of the European Committee for Treatment and…
October 9, 2015 News by Patricia Silva, PhD New 3-Times-Per-Week Regimen For Teva’s Copaxone Safe, Effective & Increases Patient Compliance #ECTRIMS2015 A Satellite Symposia entitled āDiscovering a new world in MSā presentedĀ by Teva Neuroscience was held yesterday, October 8 at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)Ā currently taking place in Barcelona, Spain, October 7 ā 10, 2015. Dr. Omar Khan from the…
October 9, 2015 News by Patricia Silva, PhD Potential MS Drug Cladribine Reported To Have No Impact on Cancer Incidence A new study recently published in the journal Neurology: Neuroimmunology & Neuroinflammation revealed that the drug Cladribine does not increase the risk of cancer in patients with multiple sclerosis (MS) as previously thought. The study was led by researchers at Queen Mary University of London (QMUL)…
October 9, 2015 News by Patricia Silva, PhD Discovering a New World in MS Through Genomics, ECTRIMS 2015 A Satellite Symposia entitled āDiscovering a new world in MSā supported by Teva Neuroscience was held yesterday, October 8, at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), currently taking place in Barcelona, Spain, October 7 ā 10, 2015. Prof. David Brassat…
October 9, 2015 News by Patricia Inacio, PhD Ocrelizumab: Could Genentech/Rocheās Experimental Drug Be the First Effective Progressive MS Therapy? Roche announced positive results for three pivotal Phase III studies of experimental MS therapy ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis (PPMS) patients at this year’s ECTRIMS 2015 conference. The results, particularly for treating PPMS, indicate that the novel therapy may represent…
October 9, 2015 News by Marta Ribeiro #ECTRIMS2015 – “Overall fat intake not significantly associated with MS risk.” – Kjetil L. Bjornevik “Overall fat intake not significantly associated with MS risk.” – Kjetil L. Bjornevik Dr. Kjetil BjĆørnevik is a professor ofĀ Neurology, Epidemiology atĀ University of Bergen. For full coverageĀ on social media forĀ #ECTRIMS2015Ā go toĀ https://bit.ly/ECTRIMS2015…
October 8, 2015 News by admin Does Sun Exposure in Early Years Delay MS Onset? Exposure to sunlight may delay the development of multiple sclerosis (MS), according to a new study from researchers in Denmark. The work, titled “Association between age at onset of multiple sclerosis and vitamin D levelārelated factors,” appeared October 7, 2015 in the journal Neurology.
October 8, 2015 News by Patricia Inacio, PhD ECTRIMS Highlights Latest Developments in Multiple Sclerosis Research The 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) is currently being held in Barcelona, from 7 to 10 of October, 2015. As the biggest scientific event focused on Multiple Sclerosis, researchers and clinicians from around the world, with more than 8,000 participants, gather…
October 8, 2015 News by Patricia Silva, PhD MS Care: A Hot Topic at #ECTRIMS2015 Three āHot Topic Sessionsā on multiple sclerosis will take place this afternoon (17:00 ā 17:45 h, GMT + 1h) at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), currently being held in Barcelona, Spain, October 7 ā 10. The first session is entitled…
October 8, 2015 News by Malika Ammam, PhD Biomarkers and Predictors For Developing Future Personalized MS Therapies Discussed at ECTRIMS 2015 New developments in the diagnosis and treatment of multiple sclerosis (MS) are being discussed at this year’sĀ 31st annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). TheĀ symposium, being held in Barcelona, Spain, will fosterĀ discussions about development of individualized therapiesĀ forĀ MS patients throughĀ a more targeted and efficient…
October 8, 2015 News by Patricia Silva, PhD Aubagio (Teriflunomide) Slows Brain Atrophy in Patients with Relapsing Multiple Sclerosis GenzymeĀ recently announced results from magnetic resonance imaging (MRI) analysis of participants in the Phase III TEMSO clinical trial showing that AubagioĀ®Ā (teriflunomide) was able to slow the loss of brain volume (or atrophy) versus a placebo over two years in patients with relapsing multiple sclerosis (RMS). Brain volume loss (BVL)…
October 8, 2015 News by Patricia Silva, PhD Biogen to Present Update on TECFIDERA (Dimethyl Fumarate) for Early Stage Relapsing-Remitting Multiple Sclerosis at ECTRIMS 2015 Biogen is scheduled to present the latest efficacy and safety profile updates on TECFIDERA (dimethyl fumarate), its lead treatmentĀ forĀ relapsing-remitting multiple sclerosis (RRMS), during theĀ 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) happening now in Barcelona, Spain until October 10, 2015. The…
October 8, 2015 News by Patricia Silva, PhD Acorda To Present New Data on MS Therapies AMPYRA and Experimental rHIgM22 at #ECTRIMS2015 Acorda Therapeutics, Inc., a company focused on therapies for neurological disorders, will present new data on its Phase 1 clinical trial evaluating rHIgM22, and five-year post-marketing safety data on AMPYRAĀ® (dalfampridine) Extended Release Tablets (10 mg) Ā at this year’sĀ 31st Congress of the European Committee for Treatment and Research in…
October 7, 2015 News by Patricia Silva, PhD Teva Pharmaceuticals to Present New Data on Multiple Sclerosis Drugs Copaxone and Laquinimod at ECTRIMS 2015 The world’sĀ largest generic medicines manufacturer,Ā Teva Pharmaceutical, is at theĀ 31st European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress currently ongoing in Barcelona, from October 7-10, 2015. Teva will be presenting the latest findings on its relapsing multiple sclerosis (MS) therapy COPAXONEĀ®Ā (glatiramer acetate injection), and product candidate for…
October 7, 2015 News by Patricia Silva, PhD Good Cholesterol Helps Prevent Brain Lesion Formation in Multiple Sclerosis A number of studies have previously suggested a negative effect of high cholesterol levels on the development of brain lesions in patients with multiple sclerosis (MS), however, little is known about the effect of HDL (high-density lipoprotein) cholesterol, or “good” cholesterol, on MS. A team of scientists from the University…
October 7, 2015 News by Patricia Silva, PhD ECTRIMS 2015 Congress: a Look at Young Investigator Session II The 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)Ā begins today, October 7, 2015 at the Centre de Convencions Internacional de Barcelona (CCIB) in Barcelona, Spain. The first day of the Congress will focus heavily onĀ Teaching Courses in several topics related to multiple sclerosis (MS)…
October 7, 2015 News by Patricia Silva, PhD Genzyme to Present vs.MS Global Survey Data on Relapsing Multiple Sclerosis Challenges at ECTRIMS Genzyme recently announced a novel worldwide initiative called vs.MS, whose goal is to increase awareness of the psychical and emotional toll of relapsing multiple sclerosis (RMS) on patients and their caregivers. To enhance the comprehension of the full burden of RMS, Genzyme conducted a large-scale survey ofĀ more than 1,500 individuals…
October 7, 2015 News by Patricia Silva, PhD ECTRIMS 2015 Congress: a Look at Young Investigator Session I The 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) will start today, 7 October 2015 at the Centre de Convencions Internacional de Barcelona (CCIB) in Barcelona, Spain. The first day of the Congress is heavily focused onĀ Teaching Courses in several topics related to multiple…
October 6, 2015 News by Patricia Silva, PhD Icometrix Collaborates with Novartis on MSmetrix Software Application, New Data at Upcoming ECTRIMS 2015 Conference Icometrix, a leader in magnetic resonance imaging (MRI) biomarkers for multiple sclerosis (MS), has recently announced a collaboration agreement with Novartis Pharma AGĀ regardingĀ MSmetrix ā a measurement tool especially designed to assess brain volume and atrophy, as well as existing, new or enlarging brain lesions in MS patients. Monitoring…
October 6, 2015 News by Patricia Silva, PhD PCORI Board Approves $83 Million for Research on Multiple Sclerosis, Hepatitis C and Rare Diseases The Patient-Centered Outcomes Research Institute (PCORI) Board of Governors recently approvedĀ an $83 million grant to support 26 patient-centered, comparative effectiveness clinical research (CER) studies on a range of diseases and patient groups. Two of these grants, totaling $29.5 million, will fund research intoĀ the care of patients infected with hepatitis…
October 5, 2015 News by Patricia Silva, PhD Study Supports High Intensity Exercise to Improve Muscle Condition in MS Patients A new study recently published in the journal PLOS ONE revealed that high intensity exercise is safe and offers clinical benefits for patients with multiple sclerosis (MS). The study is entitled āHigh Intensity Exercise in Multiple Sclerosis: Effects on Muscle Contractile Characteristics and Exercise…
October 5, 2015 News by Charles Moore Multiple Sclerosis News Today To Provide Live, On-Site Coverage Of 31st Annual #ECTRIMS2015 Congress The 31st meeting of the Congress of the European Committee for Treatment and Research in Multiple Sclerosis (#ECTRIMS2015) is being held this week from October 7 to 10 inĀ Barcelona, Spain. The conference was last held in the Catalonian capital in 1992. Multiple Sclerosis News Today…
October 2, 2015 News by Patricia Silva, PhD Biogen to Present New Data at Upcoming ECTRIMS 2015 Congress on MS Therapies, Including TECFIDERA Biogen, a biotechnology company focused on innovative therapies for autoimmune disorders, neurodegenerative diseases and hematological conditions, recently announced that it will present new data on its multiple sclerosis (MS) portfolio of therapeutic agents at the upcoming 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis…
October 1, 2015 News by Patricia Silva, PhD FDA Accepts New Drug Application for Osmotica Pharmaceutical’s Ontinua ER for Spasticity in Multiple Sclerosis Osmotica Pharmaceutical Corp.Ā recently announced that the FDA accepted its New Drug Application (NDA) for OntinuaTMĀ ER.